BRIEF—Evaxion regains Nasdaq compliance

Denmark’s Evaxion Biotech today announced that, on February 5, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that the company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).

The notification letter confirmed that the closing bid price of the company’s American depositary shares has been at $1.00 per share or greater for 10 consecutive business days from January 22, 2024, to February 02, 2024, and that the company has regained compliance with the listing rules of the Nasdaq Capital Market.

Evaxion Biotech is a pioneering TechBio company based upon its AI platform, AI-Immunology.

Based upon AI-Immunology, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a pre-clinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options.